New Ideas. Better Medicines.

JP Morgan 2022 Healthcare Conference

January 2022

Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "contemplate," "believe," "estimate," "predict," "project," "seek," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described more fully in our periodic reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021 and quarterly report on Form 10-Q for the quarter ended September 30, 2021, particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. The forward-looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

2

CCXI -- Changing Treatment Paradigms with

Precise,Targeted Medicine

§

§

§

§

Chemoattractant receptors attract and activate tissue-damaging inflammatory cells

Our highly specific small molecule therapeutics selectively inhibit chemoattractant receptors

Precise mechanism of action - precise medicine

Anti-inflammatory,notimmunosuppressive

Our medicinal chemistry expertise now includes

developing checkpoint inhibitors for oncology

Extracellular

Cell

membrane

Chemoattractant

(e.g. C5a)

Receptor

(e.g. C5a Receptor)

Intracellular

All are Small Molecule, Orally-administered Medicines

3

CCXI Discovery Platform: Generation of a Valuable Pipeline•

THERAPEUTIC AREA

Complement Inhibition

in Orphan Diseases

Immuno-Oncology

IBD and Other

Inflammatory and

Autoimmune Diseases

DRUG /

TARGET

TAVNEOS® (avacopan) / C5aR

CCX559/

PD-L1:PD-1

CCX507 /

CCR9

CCXTBD /

CCR6

INDICATION

PRECLINICAL PHASE 1

PHASE 2 PHASE 3 Approved

ANCA-ASSOCIATED VASCULITIS

C3 GLOMERULOPATHY

SEVERE HIDRADENITIS SUPPURATIVA

LUPUS NEPHRITIS (2022)

ORALLY ADMINISTERED CHECKPONT INHIBITORS

IBD: ULCERATIVE COLITIS

TH17 DRIVEN DISEASE

4

  • Our Vision - An Integrated Biopharmaceutical Company

Change the treatment paradigm in orphan and rare disease; specifically targeting chronic inflammatory pathway while avoiding immuno-suppression

Capitalize on TAVNEOS® (avacopan) potential to address multiple disease areas in the coming years

Bring novel medicines to patients with serious diseases, addressing highest unmet needs

Continue to reward those who have backed our innovative approach

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

ChemoCentryx Inc. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2022 21:45:01 UTC.